

Manuel Battegay

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5572584/publications.pdf>

Version: 2024-02-01

355
papers

15,609
citations

23879

60
h-index

28425

109
g-index

369
all docs

369
docs citations

369
times ranked

18665
citing authors

#	ARTICLE	IF	CITATIONS
1	Identifying and Characterizing Trans Women in the Swiss HIV Cohort Study as an Epidemiologically Distinct Risk Group. <i>Clinical Infectious Diseases</i> , 2022, 74, 1468-1475.	2.9	3
2	Physiologically Based Pharmacokinetic Modelling to Investigate the Impact of the Cytokine Storm on CYP3A Drug Pharmacokinetics in COVID-19 Patients. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 579-584.	2.3	15
3	Cohort Profile Update: The Swiss HIV Cohort Study (SHCS). <i>International Journal of Epidemiology</i> , 2022, 51, 33-34j.	0.9	69
4	Anticholinergic medication use in elderly people living with HIV and self-reported neurocognitive impairment: a prospective cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 492-499.	1.3	7
5	Exercise capacity impairment after COVID-19 pneumonia is mainly caused by deconditioning. <i>European Respiratory Journal</i> , 2022, 59, 2101136.	3.1	24
6	Decreasing Incidence and Determinants of Bacterial Pneumonia in People With HIV: The Swiss HIV Cohort Study. <i>Journal of Infectious Diseases</i> , 2022, 225, 1592-1600.	1.9	4
7	A qualitative study on safety perception among healthcare workers of a tertiary academic care center during the SARS-CoV-2 pandemic. <i>Antimicrobial Resistance and Infection Control</i> , 2022, 11, 30.	1.5	4
8	Determinants of SARS-CoV-2 transmission to guide vaccination strategy in an urban area. <i>Virus Evolution</i> , 2022, 8, veac002.	2.2	7
9	Impact of Latent Tuberculosis on Diabetes. <i>Journal of Infectious Diseases</i> , 2022, 225, 2229-2234.	1.9	3
10	Similar but different: Integrated phylogenetic analysis of Austrian and Swiss HIV-1 sequences reveal differences in transmission patterns of the local HIV-1 epidemics. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, Publish Ahead of Print, .	0.9	0
11	Failure to return pillbox is a predictor of being lost to follow-up among people living with HIV on antiretroviral therapy in rural Tanzania. <i>HIV Medicine</i> , 2022, 23, 661-672.	1.0	5
12	SARS-CoV-2 Vaccine Alpha and Delta Variant Breakthrough Infections Are Rare and Mild but Can Happen Relatively Early after Vaccination. <i>Microorganisms</i> , 2022, 10, 857.	1.6	8
13	Genetic variation near CXCL12 is associated with susceptibility to HIV-related non-Hodgkin lymphoma. <i>Haematologica</i> , 2021, 106, 2233-2241.	1.7	4
14	Withholding Primary Pneumocystis Pneumonia Prophylaxis in Virologically Suppressed Patients With Human Immunodeficiency Virus: An Emulation of a Pragmatic Trial in COHERE. <i>Clinical Infectious Diseases</i> , 2021, 73, 195-202.	2.9	8
15	Prevalence of Potential Drug-Drug Interactions in Patients of the Swiss HIV Cohort Study in the Era of HIV Integrase Inhibitors. <i>Clinical Infectious Diseases</i> , 2021, 73, e2145-e2152.	2.9	9
16	Phylogenetic Cluster Analysis Identifies Virological and Behavioral Drivers of Human Immunodeficiency Virus Transmission in Men Who Have Sex With Men. <i>Clinical Infectious Diseases</i> , 2021, 72, 2175-2183.	2.9	10
17	The Role of Human Immunodeficiency Virus (HIV) Asymptomatic Status When Starting Antiretroviral Therapy on Adherence and Treatment Outcomes and Implications for Test and Treat: The Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2021, 72, 1413-1421.	2.9	2
18	Effect of ageing on antiretroviral drug pharmacokinetics using clinical data combined with modelling and simulation. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 458-470.	1.1	12

#	ARTICLE	IF	CITATIONS
19	Clinical Data Combined With Modeling and Simulation Indicate Unchanged Drug-Drug Interaction Magnitudes in the Elderly. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 471-484.	2.3	10
20	Mortality Rate in a Cohort of People Living With HIV in Rural Tanzania After Accounting for Unseen Deaths Among Those Lost to Follow-up. <i>American Journal of Epidemiology</i> , 2021, 190, 251-264.	1.6	8
21	Epidemiology and precision of SARS-CoV-2 detection following lockdown and relaxation measures. <i>Journal of Medical Virology</i> , 2021, 93, 2374-2384.	2.5	20
22	Sex Differences in Lopinavir Concentrations and Occurrence of Marked QTc Prolongation Episodes in Patients with COVID-19. <i>Drug Safety</i> , 2021, 44, 255-257.	1.4	1
23	Prescribing in COVID-19 patients: Should we take into account inflammation?. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 719-721.	1.1	0
24	Community-acquired and hospital-acquired respiratory tract infection and bloodstream infection in patients hospitalized with COVID-19 pneumonia. <i>Journal of Intensive Care</i> , 2021, 9, 10.	1.3	52
25	Analysis of SARS-CoV-2 antibodies in COVID-19 convalescent blood using a coronavirus antigen microarray. <i>Nature Communications</i> , 2021, 12, 6.	5.8	164
26	Physiologically-Based Pharmacokinetic Modeling Combined with Swiss HIV Cohort Study Data Supports No Dose Adjustment of Bictegravir in Elderly Individuals Living With HIV. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1025-1029.	2.3	8
27	Systematic screening on admission for SARS-CoV-2 to detect asymptomatic infections. <i>Antimicrobial Resistance and Infection Control</i> , 2021, 10, 44.	1.5	17
28	Physiologically-Based Pharmacokinetic Modeling to Support the Clinical Management of Drug-Drug Interactions With Bictegravir. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1231-1239.	2.3	13
29	HIV-Infected Patients Developing Tuberculosis Disease Show Early Changes in the Immune Response to Novel Mycobacterium tuberculosis Antigens. <i>Frontiers in Immunology</i> , 2021, 12, 620622.	2.2	7
30	SARS-CoV-2 outbreak in a tri-national urban area is dominated by a B.1 lineage variant linked to a mass gathering event. <i>PLoS Pathogens</i> , 2021, 17, e1009374.	2.1	36
31	Immunophenotypic characterization of TCR β T cells and MAIT cells in HIV-infected individuals developing Hodgkin's lymphoma. <i>Infectious Agents and Cancer</i> , 2021, 16, 24.	1.2	3
32	Response to a sexual risk reduction intervention provided in combination with hepatitis C treatment by HIV/HCV co-infected men who have sex with men: a reflexive thematic analysis. <i>BMC Infectious Diseases</i> , 2021, 21, 319.	1.3	11
33	Prevalence and outcomes of pregnancies in women with HIV over a 20-year period. <i>Aids</i> , 2021, 35, 2025-2033.	1.0	4
34	Global Genomic Analysis of SARS-CoV-2 RNA Dependent RNA Polymerase Evolution and Antiviral Drug Resistance. <i>Microorganisms</i> , 2021, 9, 1094.	1.6	21
35	Systematic screening of viral and human genetic variation identifies antiretroviral resistance and immune escape link. <i>ELife</i> , 2021, 10, .	2.8	3
36	No need for secondary <i>Pneumocystis jirovecii</i> pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100 cells/ μ L. <i>Journal of the International AIDS Society</i> , 2021, 24, e25726.	1.2	8

#	ARTICLE	IF	CITATIONS
37	Temporal trends of COVID-19 related in-hospital mortality and demographics in Switzerland – a retrospective single centre cohort study. <i>Swiss Medical Weekly</i> , 2021, 151, w20572.	0.8	16
38	Recognition and management of clinically significant drug–drug interactions between antiretrovirals and co-medications in a cohort of people living with HIV in rural Tanzania: a prospective questionnaire-based study. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2681-2689.	1.3	2
39	Ninety-day outcome of patients with severe COVID-19 treated with tocilizumab – a single centre cohort study. <i>Swiss Medical Weekly</i> , 2021, 151, w20550.	0.8	6
40	Lactic acidosis and hyperlactatemia associated with lamivudine accumulation and sepsis in a kidney transplant recipient – a case report and review of the literature. <i>AIDS Research and Therapy</i> , 2021, 18, 56.	0.7	4
41	Comparing Immunoassays for SARS-CoV-2 Antibody Detection in Patients with and without Laboratory-Confirmed SARS-CoV-2 Infection. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0138121.	1.8	16
42	Association of Incomplete Adherence to Antiretroviral Therapy With Cardiovascular Events and Mortality in Virologically Suppressed Persons With HIV: The Swiss HIV Cohort Study. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab032.	0.4	16
43	Analysis of inappropriate prescribing in elderly patients of the Swiss HIV Cohort Study reveals gender inequity. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 758-764.	1.3	14
44	Offering ART refill through community health workers versus clinic-based follow-up after home-based same-day ART initiation in rural Lesotho: The VIBRA cluster-randomized clinical trial. <i>PLoS Medicine</i> , 2021, 18, e1003839.	3.9	8
45	Assessing the drivers of syphilis among men who have sex with men in Switzerland reveals a key impact of screening frequency: A modelling study. <i>PLoS Computational Biology</i> , 2021, 17, e1009529.	1.5	6
46	Long-term outcome after SARS-CoV-2 infection in healthcare workers: a single centre cohort study. <i>Swiss Medical Weekly</i> , 2021, 151, w30094.	0.8	8
47	Evolution of COVID-19 mortality over time: results from the Swiss hospital surveillance system (CH-SUR). <i>Swiss Medical Weekly</i> , 2021, 151, w30105.	0.8	16
48	Morbidity associated with <i>Schistosoma mansoni</i> infection in north-eastern Democratic Republic of the Congo. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009375.	1.3	3
49	Epidemiology of <i>Schistosoma mansoni</i> infection in Ituri Province, north-eastern Democratic Republic of the Congo. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009486.	1.3	3
50	Corrigendum to: Epidemiology of Severe Acute Respiratory Syndrome Coronavirus 2 Emergence Amidst Community-Acquired Respiratory Viruses. <i>Journal of Infectious Diseases</i> , 2021, 223, 734-735.	1.9	1
51	Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. <i>PLoS ONE</i> , 2021, 16, e0261367.	1.1	3
52	Physiologically Based Pharmacokinetic Modelling to Identify Pharmacokinetic Parameters Driving Drug Exposure Changes in the Elderly. <i>Clinical Pharmacokinetics</i> , 2020, 59, 383-401.	1.6	29
53	Antibodies against HPV16E6 oncoprotein in the Swiss HIV cohort study: Kinetics and anal cancer risk prediction. <i>International Journal of Cancer</i> , 2020, 147, 757-765.	2.3	5
54	Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV. <i>Aids</i> , 2020, 34, 103-108.	1.0	18

#	ARTICLE	IF	CITATIONS
55	COVID-19 Triage and Test Center: Safety, Feasibility, and Outcomes of Low-Threshold Testing. <i>Journal of Clinical Medicine</i> , 2020, 9, 3217.	1.0	9
56	Efficacy of pragmatic same-day ring prophylaxis for adult individuals exposed to SARS-CoV-2 in Switzerland (COPEP): protocol of an open-label cluster randomised trial. <i>BMJ Open</i> , 2020, 10, e040110.	0.8	5
57	Epidemiology of Severe Acute Respiratory Syndrome Coronavirus 2 Emergence Amidst Community-Acquired Respiratory Viruses. <i>Journal of Infectious Diseases</i> , 2020, 222, 1270-1279.	1.9	64
58	Host Genomics of the HIV-1 Reservoir Size and Its Decay Rate During Suppressive Antiretroviral Treatment. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 85, 517-524.	0.9	7
59	Home-based oral self-testing for absent and declining individuals during a door-to-door HIV testing campaign in rural Lesotho (HOSENG): a cluster-randomised trial. <i>Lancet HIV</i> , 2020, 7, e752-e761.	2.1	21
60	Switch to second-line versus continued first-line antiretroviral therapy for patients with low-level HIV-1 viremia: An open-label randomized controlled trial in Lesotho. <i>PLoS Medicine</i> , 2020, 17, e1003325.	3.9	16
61	Are three antiseptic paints needed for safe preparation of the surgical field? A prospective cohort study with 239 patients. <i>Antimicrobial Resistance and Infection Control</i> , 2020, 9, 120.	1.5	4
62	Heritability of the HIV-1 reservoir size and decay under long-term suppressive ART. <i>Nature Communications</i> , 2020, 11, 5542.	5.8	5
63	Ultrasound in managing extrapulmonary tuberculosis: a randomized controlled two-center study. <i>BMC Infectious Diseases</i> , 2020, 20, 349.	1.3	6
64	Low rates of active hepatitis B and C infections among adults and children living with HIV and taking antiretroviral therapy: A multicenter screening study in Lesotho. <i>Journal of Medical Virology</i> , 2020, 92, 3857-3861.	2.5	1
65	Cohort-Derived Machine Learning Models for Individual Prediction of Chronic Kidney Disease in People Living With Human Immunodeficiency Virus: A Prospective Multicenter Cohort Study. <i>Journal of Infectious Diseases</i> , 2020, 224, 1198-1208.	1.9	5
66	Low rates of influenza vaccination uptake among healthcare workers: Distinguishing barriers between occupational groups. <i>American Journal of Infection Control</i> , 2020, 48, 1139-1143.	1.1	16
67	Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3084-3086.	1.3	43
68	Prospective assessment of loss to follow-up: incidence and associated factors in a cohort of HIV-positive adults in rural Tanzania. <i>Journal of the International AIDS Society</i> , 2020, 23, e25460.	1.2	18
69	Extrapulmonary tuberculosis in HIV-infected patients in rural Tanzania: The prospective Kilombero and Ulanga antiretroviral cohort. <i>PLoS ONE</i> , 2020, 15, e0229875.	1.1	9
70	Cefiderocol for Extensively Drug-Resistant Gram-Negative Bacterial Infections: Real-world Experience From a Case Series and Review of the Literature. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa185.	0.4	44
71	Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	50
72	High failure rates of protease inhibitor-based antiretroviral treatment in rural Tanzania – A prospective cohort study. <i>PLoS ONE</i> , 2020, 15, e0227600.	1.1	8

#	ARTICLE	IF	CITATIONS
73	Repeated Syphilis Episodes in HIV-Infected Men Who Have Sex With Men: A Multicenter Prospective Cohort Study on Risk Factors and the Potential Role of Syphilis Immunity. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa019.	0.4	18
74	Real-life management of drug-drug interactions between antiretrovirals and statins. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1972-1980.	1.3	8
75	Aging does not impact drug-drug interaction magnitudes with antiretrovirals. <i>Aids</i> , 2020, 34, 949-952.	1.0	2
76	Efficacy of COVID-19 Pathogen Inactivated Convalescent Plasma for Patients with Moderate to Severe Acute COVID-19: A Case Matched Control Study. <i>Blood</i> , 2020, 136, 29-30.	0.6	6
77	Characterising the epidemic spread of influenza A/H3N2 within a city through phylogenetics. <i>PLoS Pathogens</i> , 2020, 16, e1008984.	2.1	17
78	2019-novel Coronavirus (2019-nCoV): estimating the case fatality rate – a word of caution. <i>Swiss Medical Weekly</i> , 2020, 150, w20203.	0.8	135
79	COVID-19 epidemic in Switzerland: on the importance of testing, contact tracing and isolation. <i>Swiss Medical Weekly</i> , 2020, 150, w20225.	0.8	367
80	Reproductive number of the COVID-19 epidemic in Switzerland with a focus on the Cantons of Basel-Stadt and Basel-Landschaft. <i>Swiss Medical Weekly</i> , 2020, 150, w20271.	0.8	64
81	Early off-label treatment during pandemics? A dilemma. <i>Swiss Medical Weekly</i> , 2020, 150, w20281.	0.8	3
82	Schistosomiasis: from established diagnostic assays to emerging micro/nanotechnology-based rapid field testing for clinical management and epidemiology. <i>Precision Nanomedicine</i> , 2020, 3, 439-458.	0.4	7
83	Title is missing!. , 2020, 17, e1003325.		0
84	Title is missing!. , 2020, 17, e1003325.		0
85	Title is missing!. , 2020, 17, e1003325.		0
86	Title is missing!. , 2020, 17, e1003325.		0
87	Title is missing!. , 2020, 15, e0229875.		0
88	Title is missing!. , 2020, 15, e0229875.		0
89	Title is missing!. , 2020, 15, e0229875.		0
90	Title is missing!. , 2020, 15, e0229875.		0

#	ARTICLE	IF	CITATIONS
91	Title is missing!. , 2020, 15, e0229875.		0
92	Title is missing!. , 2020, 15, e0229875.		0
93	SPHN/PHRT: Forming a Swiss-Wide Infrastructure for Data-Driven Sepsis Research. <i>Studies in Health Technology and Informatics</i> , 2020, 270, 1163-1167.	0.2	3
94	Plea for Standardized Reporting and Justification of Propensity Score Methods. <i>Clinical Infectious Diseases</i> , 2019, 68, 710-711.	2.9	3
95	Cost Estimates for Human Immunodeficiency Virus (HIV) Care and Patient Characteristics for Health Resource Use From Linkage of Claims Data With the Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2019, 68, 827-833.	2.9	7
96	Impact of health insurance status on surgical site infection incidence: A prospective cohort study. <i>Infection Control and Hospital Epidemiology</i> , 2019, 40, 1063-1065.	1.0	0
97	Determinants of HIV-1 reservoir size and long-term dynamics during suppressive ART. <i>Nature Communications</i> , 2019, 10, 3193.	5.8	112
98	Screening HIV-positive men who have sex with men for hepatitis C re-infection risk: is a single question on condom-use enough? A sensitivity analysis. <i>BMC Infectious Diseases</i> , 2019, 19, 821.	1.3	8
99	Short-course amphotericin B in addition to sertraline and fluconazole for treatment of HIV-associated cryptococcal meningitis in rural Tanzania. <i>Mycoses</i> , 2019, 62, 1127-1132.	1.8	13
100	Safety and tolerance of lymph node biopsies from chronic HIV-1 volunteers in rural Tanzania. <i>BMC Research Notes</i> , 2019, 12, 561.	0.6	0
101	Low compliance with hepatocellular carcinoma screening guidelines in hepatitis B/C virus co-infected HIV patients with cirrhosis. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1224-1228.	1.0	15
102	Sonography to Rule Out Tuberculosis in Sub-Saharan Africa: A Prospective Observational Study. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz154.	0.4	15
103	Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. <i>Lancet, The</i> , 2019, 393, 2428-2438.	6.3	627
104	A Systematic Phylogenetic Approach to Study the Interaction of HIV-1 With Coinfections, Noncommunicable Diseases, and Opportunistic Diseases. <i>Journal of Infectious Diseases</i> , 2019, 220, 244-253.	1.9	6
105	Viral Diversity Based on Next-Generation Sequencing of HIV-1 Provides Precise Estimates of Infection Recency and Time Since Infection. <i>Journal of Infectious Diseases</i> , 2019, 220, 254-265.	1.9	27
106	Polypharmacy, Drug-Drug Interactions, and Inappropriate Drugs: New Challenges in the Aging Population With HIV. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz531.	0.4	38
107	Age-related comorbidities and mortality in people living with HIV in rural Tanzania. <i>Aids</i> , 2019, 33, 1031-1041.	1.0	18
108	HIV Transmission Chains Exhibit Greater HLA-B Homogeneity Than Randomly Expected. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 508-515.	0.9	0

#	ARTICLE	IF	CITATIONS
109	Repository Describing an Aging Population to Inform Physiologically Based Pharmacokinetic Models Considering Anatomical, Physiological, and Biological Age-Dependent Changes. <i>Clinical Pharmacokinetics</i> , 2019, 58, 483-501.	1.6	48
110	High Mortality of Non-Fournier Necrotizing Fasciitis With Enterobacteriales: Time to Rethink Classification?. <i>Clinical Infectious Diseases</i> , 2019, 69, 147-150.	2.9	9
111	Frequent Door Openings During Cardiac Surgery Are Associated With Increased Risk for Surgical Site Infection: A Prospective Observational Study. <i>Clinical Infectious Diseases</i> , 2019, 69, 290-294.	2.9	26
112	Identification of influenza urban transmission patterns by geographical, epidemiological and whole genome sequencing data: protocol for an observational study. <i>BMJ Open</i> , 2019, 9, e030913.	0.8	7
113	The rate of mother-to-child transmission of antiretroviral drug-resistant HIV strains is low in the Swiss Mother and Child HIV Cohort Study. <i>Swiss Medical Weekly</i> , 2019, 149, w20059.	0.8	4
114	Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	17
115	Prevalence and Evolution of Renal Impairment in People Living With HIV in Rural Tanzania. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy072.	0.4	9
116	Digging Out the Evidence—How Strong Is the IDSA Recommendation Against Antibiotic Prophylaxis in Basilar Skull Fracture and Cerebrospinal Fluid Leakage?. <i>Clinical Infectious Diseases</i> , 2018, 66, 1319-1320.	2.9	2
117	Direct Costs of a Contact Isolation Day: A Prospective Cost Analysis at a Swiss University Hospital. <i>Infection Control and Hospital Epidemiology</i> , 2018, 39, 101-103.	1.0	28
118	Differences in Virological and Immunological Risk Factors for Non-Hodgkin and Hodgkin Lymphoma. <i>Journal of the National Cancer Institute</i> , 2018, 110, 598-607.	3.0	12
119	Boosted darunavir, emtricitabine and tenofovir pharmacokinetics in the early and late postgastric bypass surgery periods. <i>Aids</i> , 2018, 32, 1903-1905.	1.0	7
120	Inferring the age difference in HIV transmission pairs by applying phylogenetic methods on the HIV transmission network of the Swiss HIV Cohort Study. <i>Virus Evolution</i> , 2018, 4, vey024.	2.2	17
121	Introduction to Machine Learning in Digital Healthcare Epidemiology. <i>Infection Control and Hospital Epidemiology</i> , 2018, 39, 1457-1462.	1.0	51
122	Dissecting HIV Virulence: Heritability of Setpoint Viral Load, CD4+ T-Cell Decline, and Per-Parasite Pathogenicity. <i>Molecular Biology and Evolution</i> , 2018, 35, 27-37.	3.5	37
123	Tracing HIV-1 strains that imprint broadly neutralizing antibody responses. <i>Nature</i> , 2018, 561, 406-410.	13.7	47
124	Distinct, IgG1-driven antibody response landscapes demarcate individuals with broadly HIV-1 neutralizing activity. <i>Journal of Experimental Medicine</i> , 2018, 215, 1589-1608.	4.2	29
125	Lipodystrophy Increases the Risk of CKD Development in HIV-Positive Patients in Switzerland: The LIPOKID Study. <i>Kidney International Reports</i> , 2018, 3, 1089-1099.	0.4	4
126	Using dried blood spots to facilitate therapeutic drug monitoring of antiretroviral drugs in resource-poor regions. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2729-2737.	1.3	16

#	ARTICLE	IF	CITATIONS
127	Costs versus earnings in colon surgery and coronary artery bypass grafting under a prospective payment system: Sufficient financial incentives to reduce surgical site infections?. <i>Infection Control and Hospital Epidemiology</i> , 2018, 39, 1246-1249.	1.0	2
128	Population-based outcome analysis of diffuse large B-cell lymphoma in people living with HIV infection and competent individuals. <i>Hematological Oncology</i> , 2018, 36, 757-764.	0.8	4
129	Darunavir concentrations in CSF of HIV-infected individuals when boosted with cobicistat versus ritonavir. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2574-2577.	1.3	8
130	Impact of Tenofovir on Hepatitis Delta Virus Replication in the Swiss Human Immunodeficiency Virus Cohort Study. <i>Clinical Infectious Diseases</i> , 2017, 64, 1275-1278.	2.9	23
131	Strengthening HIV therapy and care in rural Tanzania affects rates of viral suppression. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2069-2074.	1.3	11
132	Specificity of two HIV screening tests detecting simultaneously HIV-1 p24 antigen and antibodies to HIV-1 and β 2. <i>Journal of Virological Methods</i> , 2017, 249, 143-146.	1.0	8
133	Factors associated with syphilis incidence in the HIV-infected in the era of highly active antiretrovirals. <i>Medicine (United States)</i> , 2017, 96, e5849.	0.4	36
134	Dolutegravir plasma levels after gastric bypass surgery. <i>Aids</i> , 2017, 31, 1052-1054.	1.0	8
135	Hepatitis delta-associated mortality in HIV/HBV-coinfected patients. <i>Journal of Hepatology</i> , 2017, 66, 297-303.	1.8	101
136	Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes. <i>Clinical Pharmacokinetics</i> , 2017, 56, 409-420.	1.6	18
137	Previous exposure in a high-risk area for travellers' diarrhoea within the past year is associated with a significant protective effect for travellers' diarrhoea: a prospective observational cohort study in travellers to South Asia. <i>Journal of Travel Medicine</i> , 2017, 24, .	1.4	10
138	Assessing the danger of self-sustained HIV epidemics in heterosexuals by population based phylogenetic cluster analysis. <i>ELife</i> , 2017, 6, .	2.8	16
139	Increasing prevalence of infectious diseases in asylum seekers at a tertiary care hospital in Switzerland. <i>PLoS ONE</i> , 2017, 12, e0179537.	1.1	26
140	A decade of HIV care in rural Tanzania: Trends in clinical outcomes and impact of clinic optimisation in an open, prospective cohort. <i>PLoS ONE</i> , 2017, 12, e0180983.	1.1	29
141	Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study. <i>BMC Infectious Diseases</i> , 2017, 17, 476.	1.3	8
142	Prevention of mother-to-child transmission of HIV Option B+ cascade in rural Tanzania: The One Stop Clinic model. <i>PLoS ONE</i> , 2017, 12, e0181096.	1.1	29
143	Incidence and risk factors for hypertension among HIV patients in rural Tanzania - A prospective cohort study. <i>PLoS ONE</i> , 2017, 12, e0172089.	1.1	53
144	The Model for End-stage Liver Disease (MELD) as a predictor of short-term mortality in <i>Staphylococcus aureus</i> bloodstream infection: A single-centre observational study. <i>PLoS ONE</i> , 2017, 12, e0175669.	1.1	5

#	ARTICLE	IF	CITATIONS
145	Cohort profile: The Kilombero and Ulanga Antiretroviral Cohort (KIULARCO) - A prospective HIV cohort in rural Tanzania. <i>Swiss Medical Weekly</i> , 2017, 147, w14485.	0.8	27
146	Value of the Pitt Bacteraemia Score to predict short-term mortality in <i>Staphylococcus aureus</i> bloodstream infection: a validation study. <i>Swiss Medical Weekly</i> , 2017, 147, w14482.	0.8	8
147	Prevalence and Outcomes of Hepatitis B Coinfection and Associated Liver Disease Among Antiretroviral Therapy-Naïve Individuals in a Rural Tanzanian Human Immunodeficiency Virus Cohort. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw162.	0.4	18
148	Standard Genotyping Overestimates Transmission of <i>Mycobacterium tuberculosis</i> among Immigrants in a Low-Incidence Country. <i>Journal of Clinical Microbiology</i> , 2016, 54, 1862-1870.	1.8	94
149	Successful Prevention of Transmission of Integrase Resistance in the Swiss HIV Cohort Study. <i>Journal of Infectious Diseases</i> , 2016, 214, 399-402.	1.9	47
150	Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia. <i>Clinical Infectious Diseases</i> , 2016, 63, ciw519.	2.9	20
151	Determinants of HIV-1 broadly neutralizing antibody induction. <i>Nature Medicine</i> , 2016, 22, 1260-1267.	15.2	133
152	Hepatitis C virus transmission among human immunodeficiency virus-infected men who have sex with men: Modeling the effect of behavioral and treatment interventions. <i>Hepatology</i> , 2016, 64, 1856-1869.	3.6	82
153	Liver fibrosis in treatment-naïve HIV-infected and HIV/HBV co-infected patients: Zambia and Switzerland compared. <i>International Journal of Infectious Diseases</i> , 2016, 51, 97-102.	1.5	18
154	Low-Dose Acetylsalicylic Acid Treatment and Impact on Short-Term Mortality in <i>Staphylococcus aureus</i> Bloodstream Infection. <i>Critical Care Medicine</i> , 2016, 44, 773-781.	0.4	22
155	Trends in Incidences and Risk Factors for Hepatocellular Carcinoma and Other Liver Events in HIV and Hepatitis C Virus-coinfected Individuals From 2001 to 2014: A Multicohort Study. <i>Clinical Infectious Diseases</i> , 2016, 63, 821-829.	2.9	48
156	Dually Active HIV/HBV Antiretrovirals as Protection Against Incident Hepatitis B Infections: Potential for Prophylaxis. <i>Journal of Infectious Diseases</i> , 2016, 214, 599-606.	1.9	34
157	Ability to Work and Employment Rates in Human Immunodeficiency Virus (HIV)-1-Infected Individuals Receiving Combination Antiretroviral Therapy: The Swiss HIV Cohort Study. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw022.	0.4	15
158	A Case Series of Acquired Drug Resistance-Associated Mutations in Human Immunodeficiency Virus-Infected Children: An Emerging Public Health Concern in Rural Africa. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofv199.	0.4	3
159	Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1352-1360.	1.3	4
160	Emergence of Acquired HIV-1 Drug Resistance Almost Stopped in Switzerland: A 15-Year Prospective Cohort Analysis. <i>Clinical Infectious Diseases</i> , 2016, 62, 1310-1317.	2.9	52
161	HIV-1 Transmission During Recent Infection and During Treatment Interruptions as Major Drivers of New Infections in the Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2016, 62, 115-122.	2.9	60
162	Ebola vaccination. <i>Lancet</i> , The, 2015, 386, 2478-2480.	6.3	0

#	ARTICLE	IF	CITATIONS
163	Strong Impact of Smoking on Multimorbidity and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Individuals in Comparison With the General Population. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv108.	0.4	38
164	HIV resistance testing and detected drug resistance in Europe. <i>Aids</i> , 2015, 29, 1379-1389.	1.0	12
165	Self-reported nonadherence to antiretroviral therapy as a predictor of viral failure and mortality. <i>Aids</i> , 2015, 29, 2195-2200.	1.0	58
166	The HIV care cascade in Switzerland. <i>Aids</i> , 2015, 29, 2509-2515.	1.0	72
167	Reasons for late presentation to HIV care in Switzerland. <i>Journal of the International AIDS Society</i> , 2015, 18, 20317.	1.2	52
168	A Bundle of Services Increased Ascertainment of Tuberculosis among HIV-Infected Individuals Enrolled in a HIV Cohort in Rural Sub-Saharan Africa. <i>PLoS ONE</i> , 2015, 10, e0123275.	1.1	23
169	Influenza vaccine response profiles are affected by vaccine preparation and preexisting immunity, but not HIV infection. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 391-396.	1.4	15
170	Cryptococcal Antigenemia in Immunocompromised Human Immunodeficiency Virus Patients in Rural Tanzania: A Preventable Cause of Early Mortality. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv046.	0.4	68
171	Transient detectable viremia and the risk of viral rebound in patients from the Swiss HIV Cohort Study. <i>BMC Infectious Diseases</i> , 2015, 15, 382.	1.3	29
172	Assessing the Paradox Between Transmitted and Acquired HIV Type 1 Drug Resistance Mutations in the Swiss HIV Cohort Study From 1998 to 2012. <i>Journal of Infectious Diseases</i> , 2015, 212, 28-38.	1.9	61
173	Etravirine: a good option for concomitant use with chemotherapy for Hodgkin's lymphoma. <i>International Journal of STD and AIDS</i> , 2015, 26, 212-214.	0.5	5
174	The Interplay Between Host Genetic Variation, Viral Replication, and Microbial Translocation in Untreated HIV-Infected Individuals. <i>Journal of Infectious Diseases</i> , 2015, 212, 578-584.	1.9	20
175	Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naïve adults. <i>Aids</i> , 2015, 29, 193-200.	1.0	13
176	HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons. <i>BMC Gastroenterology</i> , 2015, 15, 79.	0.8	18
177	Assessing efficacy of different nucleos(t)ide backbones in NNRTI-containing regimens in the Swiss HIV Cohort Study. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, dkv257.	1.3	6
178	T cells specific for different latent and lytic viral proteins efficiently control Epstein-Barr virus-transformed B cells. <i>Cytotherapy</i> , 2015, 17, 1280-1291.	0.3	11
179	A Diagnostic HIV-1 Tropism System Based on Sequence Relatedness. <i>Journal of Clinical Microbiology</i> , 2015, 53, 597-610.	1.8	8
180	Interactions of the hepatitis C virus protease inhibitor faldaprevir with cytochrome P450 enzymes: In vitro and in vivo correlation. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 467-477.	1.0	8

#	ARTICLE	IF	CITATIONS
181	Limitations in Study on Benefits of Clindamycin. <i>Clinical Infectious Diseases</i> , 2015, 60, 323-323.	2.9	1
182	Disseminated tuberculosis in an HIV-infected child: rifampicin resistance detected by GeneXpert in a lymph node aspirate but not in cerebrospinal fluid. <i>BMJ Case Reports</i> , 2015, 2015, bcr2014207997.	0.2	1
183	Acute kidney injury KDIGO stage 2 to 3 in HIV-positive patients treated with cART – a case series over 11 years in a cohort of 1,153 patients. <i>Swiss Medical Weekly</i> , 2015, 145, w14135.	0.8	6
184	Choice of initial therapy. <i>Journal of the International AIDS Society</i> , 2014, 17, 19488.	1.2	2
185	Disentangling Human Tolerance and Resistance Against HIV. <i>PLoS Biology</i> , 2014, 12, e1001951.	2.6	53
186	IL-28B is a Key Regulator of B- and T-Cell Vaccine Responses against Influenza. <i>PLoS Pathogens</i> , 2014, 10, e1004556.	2.1	108
187	A short tool to screen HIV-infected patients for mild neurocognitive disorders – a pilot study. <i>BMC Psychology</i> , 2014, 2, 21.	0.9	6
188	Thrombocytopenia is associated with an increased risk of cancer during treated HIV disease. <i>Aids</i> , 2014, 28, 2565-2571.	1.0	9
189	Treatment-Naive Individuals Are the Major Source of Transmitted HIV-1 Drug Resistance in Men Who Have Sex With Men in the Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2014, 58, 285-294.	2.9	75
190	Clustering of HCV coinfections on HIV phylogeny indicates domestic and sexual transmission of HCV. <i>International Journal of Epidemiology</i> , 2014, 43, 887-896.	0.9	36
191	Vaccine adjuvants – understanding molecular mechanisms to improve vaccines. <i>Swiss Medical Weekly</i> , 2014, 144, w13940.	0.8	24
192	Higher Risk of Incident Hepatitis C Virus Coinfection Among Men Who Have Sex With Men, in Whom the HIV Genetic Bottleneck at Transmission Was Wide. <i>Journal of Infectious Diseases</i> , 2014, 210, 1555-1561.	1.9	16
193	Co-Trimoxazole Prophylaxis Is Associated with Reduced Risk of Incident Tuberculosis in Participants in the Swiss HIV Cohort Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2363-2368.	1.4	34
194	Long-term Mortality in HIV-Positive Individuals Virally Suppressed for >3 Years With Incomplete CD4 Recovery. <i>Clinical Infectious Diseases</i> , 2014, 58, 1312-1321.	2.9	140
195	Clinical Assessment of Potential Drug Interactions of Faldaprevir, a Hepatitis C Virus Protease Inhibitor, With Darunavir/Ritonavir, Efavirenz, and Tenofovir. <i>Clinical Infectious Diseases</i> , 2014, 59, 1420-1428.	2.9	4
196	Does HIV antiretroviral therapy still need its backbone?. <i>Lancet, The</i> , 2014, 384, 1908-1910.	6.3	4
197	Virologic and Immunologic Responses in Treatment-Naive Patients to Ritonavir-Boosted Atazanavir or Efavirenz With a Common Backbone. <i>HIV Clinical Trials</i> , 2014, 15, 92-103.	2.0	4
198	Surgical and Antimicrobial Treatment of Prosthetic Vascular Graft Infections at Different Surgical Sites: A Retrospective Study of Treatment Outcomes. <i>PLoS ONE</i> , 2014, 9, e112947.	1.1	69

#	ARTICLE	IF	CITATIONS
199	Enterococci, Clostridium difficile and ESBL-producing bacteria: epidemiology, clinical impact and prevention in ICU patients. Swiss Medical Weekly, 2014, 144, w14009.	0.8	22
200	Symptom manageability in Swiss HIV-infected patients. Applied Nursing Research, 2013, 26, 110-115.	1.0	4
201	The Brain Entry of HIV-1 Protease Inhibitors Is Facilitated When Used in Combination. Molecular Pharmaceutics, 2013, 10, 2340-2349.	2.3	20
202	The Individualized Genetic Barrier Predicts Treatment Response in a Large Cohort of HIV-1 Infected Patients. PLoS Computational Biology, 2013, 9, e1003203.	1.5	19
203	HIV Infection Disrupts the Sympatric Host-Pathogen Relationship in Human Tuberculosis. PLoS Genetics, 2013, 9, e1003318.	1.5	78
204	The Incidence of AIDS-Defining Illnesses at a Current CD4 Count ≥ 200 Cells/ μ L in the Post-Combination Antiretroviral Therapy Era. Clinical Infectious Diseases, 2013, 57, 1038-1047.	2.9	92
205	Viral Hepatitis and Rapid Diagnostic Test Based Screening for HBsAg in HIV-infected Patients in Rural Tanzania. PLoS ONE, 2013, 8, e58468.	1.1	36
206	Low Levels of Mannan-Binding Lectin or Ficolins Are Not Associated with an Increased Risk of Cytomegalovirus Disease in HIV-Infected Patients. PLoS ONE, 2013, 8, e51983.	1.1	8
207	Uptake of guidelines on prevention of mother-to-child transmission of HIV in rural Tanzania: time for change. Swiss Medical Weekly, 2013, 143, w13775.	0.8	16
208	Role of retroviral restriction factors in the interferon- λ -mediated suppression of HIV-1 in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 3035-3040.	3.3	129
209	Incidence of HIV-1 Drug Resistance Among Antiretroviral Treatment-Naive Individuals Starting Modern Therapy Combinations. Clinical Infectious Diseases, 2012, 54, 131-140.	2.9	32
210	Mycobacterium tuberculosis Transmission in a Country with Low Tuberculosis Incidence: Role of Immigration and HIV Infection. Journal of Clinical Microbiology, 2012, 50, 388-395.	1.8	41
211	Beneficial course of two cases of HIV-associated multicentric Castleman disease treated with HIV antiretroviral therapy. Aids, 2012, 26, 1449-1450.	1.0	2
212	Lung Resection in Hematologic Patients With Pulmonary Invasive Fungal Disease. Chest, 2012, 142, 988-995.	0.4	17
213	Efavirenz in an Obese HIV-Infected Patient - a Report and An <i>In Vitro</i> / <i>In Vivo</i> Extrapolation Model Indicate Risk of Underdosing. Antiviral Therapy, 2012, 17, 1381-1384.	0.6	15
214	Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir. Aids, 2012, 26, 567-575.	1.0	68
215	No Risk of Surgical Site Infections From Residual Bacteria After Disinfection With Povidone-Iodine-Alcohol in 1014 Cases. Annals of Surgery, 2012, 255, 565-569.	2.1	29
216	Determinants of Sustained Viral Suppression in HIV-Infected Patients with Self-Reported Poor Adherence to Antiretroviral Therapy. PLoS ONE, 2012, 7, e29186.	1.1	21

#	ARTICLE	IF	CITATIONS
217	Genetic Diversity of EBV-Encoded LMP1 in the Swiss HIV Cohort Study and Implication for NF- κ B Activation. <i>PLoS ONE</i> , 2012, 7, e32168.	1.1	20
218	Emergence of Glutaraldehyde-Resistant <i>Pseudomonas aeruginosa</i> . <i>Infection Control and Hospital Epidemiology</i> , 2011, 32, 1173-1178.	1.0	25
219	A Comparison of Initial Antiretroviral Therapy in the Swiss HIV Cohort Study and the Recommendations of the International AIDS Society-USA. <i>PLoS ONE</i> , 2011, 6, e27903.	1.1	21
220	Effect of Early Antiretroviral Therapy during Primary HIV-1 Infection on Cell-Associated HIV-1 Dna and Plasma HIV-1 Rna. <i>Antiviral Therapy</i> , 2011, 16, 535-545.	0.6	77
221	Bioavailability of Extended-Release Nevirapine 400 and 300 mg in HIV-1: A Multicenter, Open-Label Study. <i>Clinical Therapeutics</i> , 2011, 33, 1308-1320.	1.1	10
222	Estimating the net contribution of interleukin-28B variation to spontaneous hepatitis C virus clearance. <i>Hepatology</i> , 2011, 53, 1446-1454.	3.6	56
223	The Role of Migration and Domestic Transmission in the Spread of HIV-1 Non-B Subtypes in Switzerland. <i>Journal of Infectious Diseases</i> , 2011, 204, 1095-1103.	1.9	74
224	Interruptions of cART limits CD4 T-cell recovery and increases the risk for opportunistic complications and death. <i>Aids</i> , 2011, 25, 441-451.	1.0	34
225	Ageing with HIV: medication use and risk for potential drug-drug interactions. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 2107-2111.	1.3	131
226	Systemic antibody responses to gut commensal bacteria during chronic HIV-1 infection. <i>Gut</i> , 2011, 60, 1506-1519.	6.1	60
227	Morbidity and Aging in HIV-Infected Persons: The Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2011, 53, 1130-1139.	2.9	525
228	Ambiguous Nucleotide Calls From Population-based Sequencing of HIV-1 are a Marker for Viral Diversity and the Age of Infection. <i>Clinical Infectious Diseases</i> , 2011, 52, 532-539.	2.9	127
229	Comparative transcriptomics of extreme phenotypes of human HIV-1 infection and SIV infection in sooty mangabey and rhesus macaque. <i>Journal of Clinical Investigation</i> , 2011, 121, 2391-2400.	3.9	168
230	Early Antiretroviral Therapy During Primary HIV-1 Infection Results in a Transient Reduction of the Viral Setpoint upon Treatment Interruption. <i>PLoS ONE</i> , 2011, 6, e27463.	1.1	46
231	Virosomal influenza-vaccine induced immunity in HIV-infected individuals with high versus low CD4+ T-cell counts: clues towards a rational vaccination strategy. <i>Aids</i> , 2010, 24, 2287-2289.	1.0	9
232	HIV-positive child with epidermodysplasia verruciformis-like lesions and homozygous mutation in TMC6. <i>Aids</i> , 2010, 24, 2758-2760.	1.0	5
233	Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2010, 15, 413-423.	0.6	172
234	Randomized trial of a computerized coronary heart disease risk assessment tool in HIV-infected patients receiving combination antiretroviral therapy. <i>Antiviral Therapy</i> , 2010, 15, 31-40.	0.6	12

#	ARTICLE	IF	CITATIONS
235	Impact of a national HIV voluntary counselling and testing (VCT) campaign on VCT in a rural hospital in Tanzania. <i>Tropical Medicine and International Health</i> , 2010, 15, 567-573.	1.0	21
236	A rifampicin-containing antibiotic treatment improves outcome of staphylococcal deep sternal wound infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1799-1806.	1.3	37
237	Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy. <i>Gut</i> , 2010, 59, 1252-1258.	6.1	46
238	Low Postseroconversion CD4 Count and Rapid Decrease of CD4 Density Identify HIV ⁺ Fast Progressors. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 997-1005.	0.5	9
239	Incidence and Risk Factors for Chronic Elevation of Alanine Aminotransferase Levels in HIV-Infected Persons without Hepatitis B or C Virus Co-infection. <i>Clinical Infectious Diseases</i> , 2010, 50, 502-511.	2.9	88
240	Phylogenetic Approach Reveals That Virus Genotype Largely Determines HIV Set-Point Viral Load. <i>PLoS Pathogens</i> , 2010, 6, e1001123.	2.1	108
241	Antiretroviral monotherapy: should we abandon the principles of successful antiretroviral therapy?. <i>Aids</i> , 2010, 24, 1057-1059.	1.0	3
242	Suicide in HIV-Infected Individuals and the General Population in Switzerland, 1988-2008. <i>American Journal of Psychiatry</i> , 2010, 167, 143-150.	4.0	104
243	Extended Spectrum β -Lactamase-producing <i>Escherichia coli</i> in Neonatal Care Unit. <i>Emerging Infectious Diseases</i> , 2010, 16, 1758-1760.	2.0	41
244	JC Virus-Specific Immune Responses in Human Immunodeficiency Virus Type 1 Patients with Progressive Multifocal Leukoencephalopathy. <i>Journal of Virology</i> , 2009, 83, 4404-4411.	1.5	74
245	Incidence and Outcome of Progressive Multifocal Leukoencephalopathy over 20 Years of the Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2009, 48, 1459-1466.	2.9	123
246	Long-Term Trends of HIV Type 1 Drug Resistance Prevalence among Antiretroviral Treatment-Experienced Patients in Switzerland. <i>Clinical Infectious Diseases</i> , 2009, 48, 979-987.	2.9	43
247	Contribution of Genome-Wide Significant Single-Nucleotide Polymorphisms and Antiretroviral Therapy to Dyslipidemia in HIV-Infected Individuals. <i>Circulation: Cardiovascular Genetics</i> , 2009, 2, 621-628.	5.1	38
248	Drug-Drug Interaction in a Kidney Transplant Recipient Receiving HIV Salvage Therapy and Tacrolimus. <i>American Journal of Kidney Diseases</i> , 2009, 54, e1-e4.	2.1	43
249	Hierarchical modeling gave plausible estimates of associations between metabolic syndrome and components of antiretroviral therapy. <i>Journal of Clinical Epidemiology</i> , 2009, 62, 632-641.	2.4	14
250	Outcomes of early switching from intravenous to oral antibiotics on medical wards. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 188-199.	1.3	128
251	Scabies Outbreak in an Intensive Care Unit with 1,659 Exposed Individuals—Key Factors for Controlling the Outbreak. <i>Infection Control and Hospital Epidemiology</i> , 2009, 30, 354-360.	1.0	50
252	A Pain in the Neck: Probiotics for Ulcerative Colitis. <i>Annals of Internal Medicine</i> , 2009, 151, 895.	2.0	13

#	ARTICLE	IF	CITATIONS
253	Virological and immunological responses to efavirenz or boosted lopinavir as first-line therapy for patients with HIV. <i>Antiviral Therapy</i> , 2009, 14, 771-779.	0.6	9
254	Discontinuation of Enfuvirtide in Heavily Pretreated HIV-Infected Individuals. <i>HIV Clinical Trials</i> , 2009, 10, 207-214.	2.0	3
255	Hodgkin lymphoma in the Swiss HIV Cohort Study. <i>Blood</i> , 2009, 113, 5737-5742.	0.6	92
256	Safety and Efficacy of Once-Daily Nevirapine Dosing: A Multicohort Study. <i>Antiviral Therapy</i> , 2009, 14, 931-938.	0.6	20
257	Impact of Previous Virological Treatment Failures and Adherence on the Outcome of Antiretroviral Therapy in 2007. <i>PLoS ONE</i> , 2009, 4, e8275.	1.1	18
258	Self-reported alcohol consumption and its association with adherence and outcome of antiretroviral therapy in the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2009, 14, 349-357.	0.6	45
259	Polyfunctional HCV-specific T cell responses are associated with effective control of HCV replication. <i>European Journal of Immunology</i> , 2008, 38, 2665-2677.	1.6	138
260	Round-table multidisciplinary counselling of couples with HIV prior to assisted reproduction. <i>Reproductive BioMedicine Online</i> , 2008, 17, 167-174.	1.1	6
261	Characteristics and Treatment Outcome of Cerebrospinal Fluid Shunt-Associated Infections in Adults: A Retrospective Analysis over an 11-Year Period. <i>Clinical Infectious Diseases</i> , 2008, 47, 73-82.	2.9	226
262	Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. <i>Aids</i> , 2008, 22, 301-306.	1.0	124
263	Durability and Outcome of Initial Antiretroviral Treatments Received during 2000-2005 by Patients in the Swiss HIV Cohort Study. <i>Journal of Infectious Diseases</i> , 2008, 197, 1685-1694.	1.9	95
264	Factors Associated with the Emergence of K65R in Patients with HIV-1 Infection Treated with Combination Antiretroviral Therapy Containing Tenofovir. <i>Clinical Infectious Diseases</i> , 2008, 46, 1299-1309.	2.9	35
265	<i>Homozygosity Is Associated with an Impaired CD4 T Cell Recovery after Initiation of Antiretroviral Therapy. Clinical Infectious Diseases</i> , 2008, 46, 1921-1925.	2.9	28
266	CD4 ⁺ T Cell Count Recovery in HIV Type 1-Infected Patients Is Independent of Class of Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2008, 47, 1093-1101.	2.9	46
267	Antiretroviral therapy of late presenters with advanced HIV disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 41-44.	1.3	130
268	Effects of cognitive behavioral stress management on HIV-1 RNA, CD4 cell counts and psychosocial parameters of HIV-infected persons. <i>Aids</i> , 2008, 22, 767-775.	1.0	48
269	Response to combination antiretroviral therapy: variation by age. <i>Aids</i> , 2008, 22, 1463-1473.	1.0	188
270	Self-Reported Non-Adherence to Antiretroviral Therapy Repeatedly assessed by Two Questions Predicts Treatment Failure in Virologically Suppressed Patients. <i>Antiviral Therapy</i> , 2008, 13, 77-86.	0.6	100

#	ARTICLE	IF	CITATIONS
271	HIV Patients Developing Primary CNS Lymphoma Lack EBV-Specific CD4+ T Cell Function Irrespective of Absolute CD4+ T Cell Counts. <i>PLoS Medicine</i> , 2007, 4, e96.	3.9	81
272	Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST. <i>Aids</i> , 2007, 21, 1977-1980.	1.0	19
273	Treatment initiation with zidovudine-containing potent antiretroviral therapy impairs CD4 cell count recovery but not clinical efficacy. <i>Aids</i> , 2007, 21, 939-946.	1.0	30
274	Ecological Study of the Predictors of Successful Management of Dyslipidemia in HIV-Infected Patients on ART: the Swiss HIV Cohort Study. <i>HIV Clinical Trials</i> , 2007, 8, 77-85.	2.0	8
275	Increased Epstein-Barr virus-specific antibody-levels in HIV-infected individuals developing primary central nervous system lymphoma. <i>Aids</i> , 2007, 21, 1664-1666.	1.0	4
276	Two versus three-class antiretroviral therapy in antiretroviral-naive patients in different time periods of the HAART era. <i>Aids</i> , 2007, 21, 537-538.	1.0	1
277	Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study. <i>Aids</i> , 2007, 21, 2201-2207.	1.0	7
278	TB in a Low-Incidence Country: Differences Between New Immigrants, Foreign-Born Residents and Native Residents. <i>American Journal of Medicine</i> , 2007, 120, 350-356.	0.6	42
279	Cost-Effectiveness of Genotypic Antiretroviral Resistance Testing in HIV-Infected Patients with Treatment Failure. <i>PLoS ONE</i> , 2007, 2, e173.	1.1	31
280	Late presentation of HIV-infected individuals. <i>Antiviral Therapy</i> , 2007, 12, 841-51.	0.6	27
281	Late Presentation of HIV-Infected Individuals. <i>Antiviral Therapy</i> , 2007, 12, 841-851.	0.6	49
282	Treatment and Prognosis of AIDS-Related Lymphoma in the Era of Highly Active Antiretroviral Therapy: Findings from the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2007, 12, 931-940.	0.6	26
283	CD4 ⁺ T-Cell Count Increase in HIV-1-Infected Patients with Suppressed Viral Load Within 1 year after start of antiretroviral therapy. <i>Antiviral Therapy</i> , 2007, 12, 889-898.	0.6	27
284	Immunological recovery and antiretroviral therapy in HIV-1 infection. <i>Lancet Infectious Diseases</i> , The, 2006, 6, 280-287.	4.6	220
285	Clinical spectrum of the immune restoration inflammatory syndrome. <i>Current Opinion in HIV and AIDS</i> , 2006, 1, 56-61.	1.5	11
286	Once-daily directly observed therapy lopinavir/ritonavir plus indinavir as a protease inhibitor-only salvage therapy in heavily pretreated HIV-1-infected patients: a pilot study. <i>Aids</i> , 2006, 20, 129-131.	1.0	7
287	Evidence of Viral Adaptation to HLA Class I-Restricted Immune Pressure in Chronic Hepatitis C Virus Infection. <i>Journal of Virology</i> , 2006, 80, 11094-11104.	1.5	103
288	A Longitudinal Analysis of Healthcare Costs after Treatment Optimization following Genotypic Antiretroviral Resistance Testing: Does Resistance Testing pay off?. <i>Antiviral Therapy</i> , 2006, 11, 305-314.	0.6	10

#	ARTICLE	IF	CITATIONS
289	Eligibility for and Outcome of Hepatitis C Treatment of HIV-Coinfected Individuals in Clinical Practice: The Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2006, 11, 131-142.	0.6	35
290	A Smoking Cessation Programme in HIV-Infected Individuals: A Pilot Study. <i>Antiviral Therapy</i> , 2006, 11, 787-796.	0.6	63
291	Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir. <i>Aids</i> , 2005, 19, 1987-1994.	1.0	29
292	Symptom Management in HIV/AIDS. <i>Advances in Nursing Science</i> , 2005, 28, 333-344.	0.6	45
293	Characteristics, Determinants, and Clinical Relevance of CD4 T Cell Recovery to <500 Cells/ÅL in HIV Type 1-Infected Individuals Receiving Potent Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2005, 41, 361-372.	2.9	285
294	Contrary to HIV, hepatitis C virus is not associated with erythrocytes in vivo. <i>Journal of Hepatology</i> , 2005, 42, 150-152.	1.8	2
295	Lipid Profiles for Antiretroviral-Naive Patients Starting Pi- and Nnrti-Based Therapy in the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2005, 10, 585-591.	0.6	95
296	Body Fat Changes among Antiretroviral-Naive Patients on Pi- and Nnrti-Based Haart in the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2005, 10, 73-81.	0.6	30
297	Intranasal Influenza Vaccine in a Working Population. <i>Clinical Infectious Diseases</i> , 2004, 38, 974-980.	2.9	36
298	Editorial Commentary: Sexual Risk Behavior in HIV-Infected Injection Drug Users. <i>Clinical Infectious Diseases</i> , 2004, 38, 1175-1177.	2.9	9
299	Acute Renal Failure on Immune Reconstitution in an HIV-Positive Patient with Miliary Tuberculosis. <i>Clinical Infectious Diseases</i> , 2004, 38, e32-e35.	2.9	60
300	Protease inhibitor-sparing simplified maintenance therapy: a need for perspective. <i>Journal of Antimicrobial Chemotherapy</i> , 2004, 54, 303-305.	1.3	7
301	Immune Reconstitution in HIV-Infected Patients. <i>Clinical Infectious Diseases</i> , 2004, 38, 1159-1166.	2.9	321
302	Carriage of <i>Staphylococcus aureus</i> Among Injection Drug Users: Lower Prevalence in an Injection Heroin Maintenance Program Than in an Oral Methadone Program. <i>Infection Control and Hospital Epidemiology</i> , 2004, 25, 133-137.	1.0	19
303	The decision to get vaccinated against influenza. <i>American Journal of Medicine</i> , 2004, 116, 856-858.	0.6	11
304	Chest pain after travel to the tropics. <i>Lancet, The</i> , 2004, 363, 1198.	6.3	10
305	Productivity costs and determinants of productivity in HIV-infected patients. <i>Clinical Therapeutics</i> , 2004, 26, 791-800.	1.1	26
306	The role of CFTR and SPINK-1 mutations in pancreatic disorders in HIV-positive patients. <i>Aids</i> , 2004, 18, 1521-1527.	1.0	29

#	ARTICLE	IF	CITATIONS
307	Is unsafe sexual behaviour increasing among HIV-infected individuals?. <i>Aids</i> , 2004, 18, 1707-1714.	1.0	31
308	Gynecomastia and potent antiretroviral therapy. <i>Aids</i> , 2004, 18, 1347-1349.	1.0	14
309	All cause mortality in the Swiss HIV cohort study from 1990 to 2001 in comparison with the Swiss population. <i>Aids</i> , 2004, 18, 1835-1843.	1.0	75
310	Epstein-Barr virus load correlating with clinical manifestation and treatment response in a patient with angioimmunoblastic T-cell lymphoma. <i>Antiviral Therapy</i> , 2004, 9, 453-9.	0.6	2
311	Epstein-Barr Virus Load Correlating with Clinical Manifestation and Treatment Response in a Patient with Angioimmunoblastic T-Cell Lymphoma. <i>Antiviral Therapy</i> , 2004, 9, 453-459.	0.6	14
312	Long-Term Virological Response to Multiple Sequential Regimens of Highly Active Antiretroviral Therapy for HIV Infection. <i>Antiviral Therapy</i> , 2004, 9, 263-274.	0.6	11
313	Infrequent Transmission of HIV-1 Drug-Resistant Variants. <i>Antiviral Therapy</i> , 2004, 9, 375-384.	0.6	59
314	Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population. <i>Lancet</i> , The, 2003, 362, 877-878.	6.3	101
315	Intravenous opiate maintenance in a cohort of injecting drug addicts. <i>Drug and Alcohol Dependence</i> , 2003, 69, 183-188.	1.6	13
316	Migrants from Sub-Saharan Africa in the Swiss HIV Cohort Study. <i>Aids</i> , 2003, 17, 2237-2244.	1.0	76
317	Meta-analysis of randomized controlled trials of simplified versus continued protease inhibitor-based antiretroviral therapy in HIV-1-infected patients. <i>Aids</i> , 2003, 17, 2451-2459.	1.0	49
318	Evaluation of unstructured medical school examinations: prospective observational study. <i>Swiss Medical Weekly</i> , 2003, 133, 184-7.	0.8	4
319	Infections Requiring Hospitalization of Injection Drug Users Who Participated in an Injection Opiate Maintenance Program. <i>Clinical Infectious Diseases</i> , 2002, 34, 711-713.	2.9	26
320	Potential benefit and limitations of a broad access to potent antiretroviral therapy in developing countries. <i>Expert Opinion on Investigational Drugs</i> , 2002, 11, 1303-1313.	1.9	6
321	Association of a pool of HIV-1 with erythrocytes in vivo: a cohort study. <i>Lancet</i> , The, 2002, 359, 2230-2234.	6.3	76
322	Inflammatory Bowel Perforation During Immune Restoration After One Year of Antiretroviral and Antituberculous Therapy in an HIV-1-Infected Patient. <i>Diseases of the Colon and Rectum</i> , 2002, 45, 977-978.	0.7	30
323	Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. <i>Aids</i> , 2002, 16, 1967-1969.	1.0	107
324	Evidence for prevention and screening: recommendations in adults. <i>Swiss Medical Weekly</i> , 2002, 132, 363-73.	0.8	7

#	ARTICLE	IF	CITATIONS
325	Onset and pattern of substance use in intravenous drug users of an opiate maintenance program. <i>Drug and Alcohol Dependence</i> , 2001, 64, 105-109.	1.6	22
326	Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. <i>Lancet, The</i> , 2001, 358, 1322-1327.	6.3	317
327	Critical issues of HIV treatment in the era of highly active antiretroviral therapy. <i>Expert Opinion on Investigational Drugs</i> , 2001, 10, 175-183.	1.9	4
328	Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients. <i>Aids</i> , 2000, 14, 791-799.	1.0	36
329	Discontinuation of Primary Prophylaxis against <i>Pneumocystis carinii</i> Pneumonia in HIV-1 Infected Adults Treated with Combination Antiretroviral Therapy. <i>New England Journal of Medicine</i> , 1999, 340, 1301-1306.	13.9	271
330	Cost-effectiveness of azithromycin for preventing <i>Mycobacterium avium</i> complex infection in HIV-positive patients in the era of highly active antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 1999, 44, 811-817.	1.3	27
331	AIDS-Related Opportunistic Illnesses Occurring After Initiation of Potent Antiretroviral Therapy. <i>JAMA - Journal of the American Medical Association</i> , 1999, 282, 2220.	3.8	416
332	General and specific immunosuppression caused by antiviral T-cell responses. <i>Immunological Reviews</i> , 1999, 168, 305-315.	2.8	49
333	Salvage treatment against human immunodeficiency virus. <i>Annals of Medicine</i> , 1999, 31, 253-260.	1.5	9
334	Downregulation of Bcl-2, but Not of Bax or Bcl-x, Is Associated with T Lymphocyte Apoptosis in HIV Infection and Restored by Antiretroviral Therapy or by Interleukin 2. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 803-810.	0.5	38
335	Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. <i>Lancet, The</i> , 1999, 353, 863-868.	6.3	894
336	Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials. <i>Aids</i> , 1999, 13, 501-507.	1.0	237
337	Quality of life in asymptomatic patients with early HIV infection initiating antiretroviral therapy. <i>Aids</i> , 1999, 13, 1587.	1.0	24
338	HIV-1-infected patients with focal neurologic signs: diagnostic role of PCR for <i>Toxoplasma gondii</i> , Epstein-Barr virus, and JC virus. <i>Clinical Microbiology and Infection</i> , 1998, 4, 577-584.	2.8	28
339	Is CD95 or CD26 expression on T-cells a marker for HIV non- or slow-progressor status?. <i>Clinical Microbiology and Infection</i> , 1998, 4, 464-465.	2.8	0
340	Interferon-alpha activates signal transducers and activators of transcription 5 and 6 in Daudi cells. <i>FEBS Journal</i> , 1998, 254, 514-519.	0.2	68
341	Highly active antiretroviral therapy during early HIV infection reverses T-cell activation and maturation abnormalities. <i>Aids</i> , 1998, 12, 2115-2123.	1.0	89
342	Genotype distribution of hepatitis C virus infection in Greece. <i>European Journal of Gastroenterology and Hepatology</i> , 1998, 10, 75-80.	0.8	12

#	ARTICLE	IF	CITATIONS
343	Does Pregnancy Influence the Course of HIV Infection? Evidence from Two Large Swiss Cohort Studies. <i>Obstetrical and Gynecological Survey</i> , 1998, 53, 671-672.	0.2	0
344	High prevalence and coinfection rate of hepatitis G and C infections in intravenous drug addicts. <i>Journal of Hepatology</i> , 1997, 26, 794-797.	1.8	57
345	Low doses of zidovudine plus didanosine are less effective than higher doses of didanosine monotherapy: a randomized trial in patients pretreated with zidovudine. <i>Clinical Microbiology and Infection</i> , 1997, 3, 629-633.	2.8	0
346	Erythema of the proximal nailfold in HIV-infected patients. <i>Journal of the American Academy of Dermatology</i> , 1996, 35, 631-633.	0.6	36
347	Antiviral Immune Responses of Mice Lacking MHC Class II or Its Associated Invariant Chain. <i>Cellular Immunology</i> , 1996, 167, 115-121.	1.4	51
348	Non-tolerant B cells cause autoimmunity in anti-CD8 IgG2a-transgenic mice. <i>European Journal of Immunology</i> , 1996, 26, 250-258.	1.6	13
349	Suppression of hepatitis C virus (HCV) replication by hepatitis D virus (HDV) in HIV-infected hemophiliacs with chronic hepatitis B and C. <i>Digestive Diseases and Sciences</i> , 1995, 40, 1583-1588.	1.1	36
350	Elimination of hepatitis delta virus infection after loss of hepatitis B surface antigen in patients with chronic delta hepatitis. <i>Journal of Medical Virology</i> , 1994, 44, 389-392.	2.5	41
351	Hepatitis delta virus RNA in serum of patients with chronic delta hepatitis. <i>Digestive Diseases and Sciences</i> , 1994, 39, 2650-2655.	1.1	9
352	Lysis of infected cells in vivo by antiviral cytolytic T cells demonstrated by release of cell internal viral proteins. <i>European Journal of Immunology</i> , 1993, 23, 1540-1545.	1.6	23
353	Enhancement of disease by neutralizing antiviral antibodies in the absence of primed antiviral cytotoxic T cells. <i>European Journal of Immunology</i> , 1993, 23, 3236-3241.	1.6	40
354	Quantification of lymphocytic choriomeningitis virus with an immunological focus assay in 24- or 96-well plates. <i>Journal of Virological Methods</i> , 1991, 33, 191-198.	1.0	446
355	Exploring the Doctor-Patient Relationship Reduces Staff Stress and Enhances Empathy When Caring for AIDS Patients. <i>Psychotherapy and Psychosomatics</i> , 1991, 56, 167-173.	4.0	8